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Abstract
Case presentation: a 75-year-old man with a 10-year history of nodular goitre was referred for clinical evaluation. The ultrasound scan 
revealed enlarged thyroid right lobe almost fully filled with a heterogeneous nodule with numerous calcifications. Fine-needle aspiration 
biopsy suggested medullary thyroid carcinoma (MTC). Before the surgery the patient was referred to the nuclear medicine department and 
somatostatin receptor imaging (SRS; 68Ga-DOTATATE) with PET/CT was performed. The scan demonstrated an increased uptake within 
the right thyroid mass. Subsequent PET/CT with 68Ga-gastrin analogue (MG48) revealed the same indications as the SRS: an increased 
alveolar uptake in the right thyroid mass without the signs of lymph node metastases. The patient underwent total thyroidectomy and 
central lymph nodes dissection. Histopathology examination confirmed the presence of MTC with vascular invasion, but without lymph 
node metastases (pT3NoMx according to the 7th edition of the AJCC Cancer Staging Manual). Immunohistochemical staining revealed 
positive reaction to calcitonin and CD56, whereas the reaction to thyroglobulin remained negative. The Ki-67 was 1%. Staining for SSTR2 
and CCK2 showed high cytoplasmic expression in both cases. 
Knowledge of the presence of CCK2 receptor in MTC patients may be an important indication for the choice of diagnostic and therapeutic 
procedures. The presence of both the receptor types, cholecystokinin-2/gastrin and somatostatin, is possibly an interesting combination 
as far as the therapeutic target is concerned. (Endokrynol Pol 2016; 67 (1): 68–71)
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Streszczenie
W pracy przedstawiono opis 75-letniego mężczyzny z dziesięcioletnią historią wola guzkowego skierowanego do Kliniki w celu badań 
kontrolnych. W badaniu USG stwierdzono powiększenie prawego płata tarczycy, wypełnionego prawie całkowicie niejednorodnym 
guzkiem z licznymi zwapnieniami. W biopsji aspiracyjnej cienkoigłowej wysunięto podejrzenie raka rdzeniastego tarczycy (MTC). 
Przed zabiegiem pacjenta skierowano do Zakładu Medycyny Nuklearnej w celu scyntygrafii receptorów somatostatynowych (SRS; 
68Ga-DOTATATE) wykonanej techniką PET/CT. W badaniu stwierdzono zwiększone gromadzenie znacznika w zmianie prawego płata 
tarczycy. Następnie wykonano badanie PET/CT z 68Ga-analogiem gastryny(MG48), stwierdzając podobnie jak w SRS, zwiększone gro-
madzenie znacznika w guzku prawego płata tarczycy, nie stwierdzono przerzutów do węzłów chłonnych. Wykonano całkowite wycięcie 
tarczycy i centralnych węzłów chłonnych. Badanie histopatologiczne potwierdziło obecność MTC z cechami inwazji naczyniowej, ale bez 
przerzutów do węzłów chłonnych (pT3NoMx według 7. edycji AJCC stopnia złośliwości). Barwienie immunohistochemiczne ujawniło 
pozytywną reakcję na kalcytoninę i CD56, podczas gdy reakcja Tg była negatywna. Ki-67 wynosiło 1%. Barwienie na obecność receptorów 
SSTR2 oraz CCK2 wykazało wysokie poziomy ekspresji cytoplazmatycznej, w obu przypadkach. 
Znajomość obecności receptora CCK2 u pacjentów z MTC może być ważna w trakcie wyboru procedur diagnostycznych i terapeutyc-
znych. Obecność obu typów receptorów cholecystokininy-2/gastryny i somatostatyny potencjalnie może być wykorzystana w leczeniu 
celowanym. (Endokrynol Pol 2016; 67 (1): 68–71)
Słowa kluczowe: rak rdzeniasty tarczycy; CCK2 receptor; receptory somatostatynowe; 68Ga; PET/CT 
Introduction
Medullary thyroid carcinoma (MTC) is a rare thyroid 
neoplasm originating from neuroendocrine parafol-
licular C-cells and secreting calcitonin, and in some 
cases also carcinoembryonic antigen (CEA). Most 
MTCs are sporadic (80%); however, they may also 
occur in hereditary form (MEN2, Multiple Endocrine 
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Neoplasia type 2). Serum calcitonin level is the most 
sensitive and specific tumour marker in the preopera-
tive diagnosis and the post-surgery follow-up [1]. The 
diagnostic imaging of MTC is still problematic. The 
sensitivity of scintigraphic imaging is strongly con-
nected with serum calcitonin level [2, 3]. More than 
75% of MTCs reveal overexpression of somatostatin 
receptors (SSTR). Cholecystokinin-2/gastrin receptor 
(CCK2R) is overexpressed in most tumours, such as 
MTC (>90%), astrocytomas (> 65%), and stromal 
ovarian cancers (100%). In such cases, gastrin recep-
tor scintigraphy gives a higher tumour detection rate 
than SRS [4, 5]. Therefore, CCK2- scintigraphy paral-
lel to SRS may improve the detection rate of MTC. 
The published data has been presenting the CCK2 
scintigraphy using 111In or 99mTc. The increased utilisa-
tion of PET/CT in oncology has led to the introduction 
of positron-emitting tracers labelled with gallium-68. 
Moreover, technical advantages (i.e. spatial resolu-
tion, attenuation correction, decreased examination 
time, and reduced radiation doses), in comparison 
to 111In or 99mTc, make 68Ga-DOTA- peptides the new 
standard in oncological diagnosis.
To our knowledge, this is the first imaging of CCK2 
receptors with PET/CT techniques in human. 
Case presentation
A 75-year-old man with a ten-year history of nodular 
goitre and hypertension was referred for a yearly 
clinical evaluation. The ultrasound scan (AIXPLORER 
system by Supersonic Imagine and 2–10 MHz linear 
transducer) revealed enlarged thyroid right lobe al-
most fully filled with a heterogeneous nodule with 
numerous calcifications. There were no signs of neck 
lymphadenopathy. Fine-needle aspiration biopsy 
(FNAB) of the right lobe nodule suggested medullary 
thyroid carcinoma. Biochemical evaluation revealed 
elevated calcitonin level 2000 pg/mL (normal 0–10), 
CEA 91.7 ng/mL (normal < 6.5), and chromogranin 
A 177.6 ng/mL (normal 19–100). The results of other 
tests such as TSH, thyroid hormones, parathormone, 
calcium, and phosphates were in the normal range. 
Diurnal excretion of metanephrines and norme-
tanephrines was not increased. There was no family 
history of thyroid disorders. Abdominal ultrasound 
and contrast-enhanced computed tomography (CT) 
scan of the abdomen did not reveal any abnormali-
ties within adrenal glands. Genetic study comprising 
routine screening within six RET proto-oncogene 
exons (exon: 10, 11, 13, 14, 15, 16) did not confirm 
any mutations. The patient underwent 68Ga-labelled 
gastrin and somatostatin analogues PET/CT for the 
preoperative staging. 
Somatostatin receptor imaging (68Ga-DOTATATE) 
with PET/CT demonstrated an increased uptake in the 
right thyroid mass (Fig. 1, A — PET MIP, C — fusion 
PET/CT). 
Subsequent PET/CT with 68Ga-gastrin analogue 
(MG48) revealed the same indications as the somato-
statin receptor — an increased alveolar uptake in the 
right thyroid mass (Fig. 1, B — PET MIP, E — fusion 
PET/CT) without the signs of lymph node metastases. 
The patient underwent total thyroidectomy and 
central lymph nodes dissection. Histopathology exami-
nation confirmed the presence of medullary thyroid car-
cinoma with vascular invasion, but without lymph node 
metastases (pT3NoMx according to the 7th edition of the 
AJCC Cancer Staging Manual). Immunohistochemical 
staining revealed positive reaction to calcitonin and 
CD56, whereas the reaction to thyroglobulin remained 
negative. The Ki-67 was 1%. Staining for SSTR2 (Fig. 1D) 
and CCK2 (Fig. 1F) showed high cytoplasmic expres-
sion in both cases. 
Discussion
Early preoperative detection of primary lesions and 
metastases before the surgery in the case of medullary 
thyroid carcinoma is still a challenge. Many different 
imaging techniques, including CT scan, MRI, PET/CT, 
or scintigraphy, are used to define the staging of MTC, 
although the sensitivity of these techniques varies. 
The aim of the paper is to report the detection of 
medullary thyroid carcinoma in the thyroid gland 
before the surgery, using two different imaging tech-
niques: gastrin (CCK2) receptor and somatostatin 
receptor visualisation with PET/CT. The fact that some 
tumours express somatostatin receptors is used to 
localise primary lesion and metastases, and therefore 
it may also allow for the use of somatostatin receptor 
analogues in the treatment [6]. The sensitivity rate of 
SRS varies and may be as low as 37% and as high as 
90% [7–9]. 
In ATA recommendations, 18FDG-PET and SRS are 
not indicated in patients with MTC suspected or di-
agnosed before the surgery [10]. However, in patients 
with elevated calcitonin level (over 400 pg/mL) it is 
necessary to perform chest and neck CT with parallel 
liver CT or MRI. PET/CT and SRS are considered to 
have lower sensitivity and higher costs. Dahlberg et 
al. performed somatostatin receptor scintigraphy using 
(111)In-octreotide in patients with MTC prior to the 
surgery. They found that SRS helped to visualise pri-
mary tumours in 84% of patients (among the 16 subjects 
that were examined). SRS detected metastases only in 
53% of patients with advanced disease; therefore, they 
concluded that preoperative use of SRS is useful, but 
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there is no indication of using it before the surgery to 
state MTC advancement [11].
MTC as a neuroendocrine tumour may produce 
different peptides and express their receptors. As well 
as somatostatin receptors, MTC expresses also gas-
trin/cholecystokinin-2 (CCK-2), glucagon-like peptide 
1 (GLP-1), or calcium-sensing receptors [12–14]. The 
presence of CCK-2 receptors was used for localising 
MTC and its metastases in different scintigraphic 
techniques. In some studies, gastrin receptor scin-
tigraphy was used to enhance the sensitivity of SRS, 
especially in situations where the SRS scans were 
negative in the presence of advanced MTC or other 
neuroendocrine tumours [4, 5, 15]. Gastrin receptor 
scintigraphy seemed to have higher specificity and 
positive predictive value, but lower sensitivity than 
SRS. This could be related to peptide structure and 
purification [5]. 
In the last decade, PET/CT scan has become more 
popular for visualisation of MTC lesions. There are 
several publications reporting the application of 18FDG 
or FDOPA or 68Ga-DOTATATE PET/CT in the evalua-
tion of neuroendocrine tumours [16, 17]. PET/CT with 
18F-DOPA seems to be the most useful imaging tech-
nique for the detection of recurrent MTC lesions, ac-
cording to Treglia et al. [18]. Using PET/CT instead of 
conventional scintigraphy increased the sensitivity of 
this detection. Parallel 68Ga-DOTATATE and 68Ga-gastrin 
analogue PET/CT may also enhance the sensitivity of 
lesion detection, although we were not able to check 
whether local or distant metastases might be easily lo-
calised using this double technique. Until now, we could 
not find any information that such a study has been 
conducted before. Visualisation using radiopeptides has 
an advantage over other imaging techniques because 
the presence of highly expressed receptors may serve 
as an additional therapeutic tool, as is the case with 
somatostatin receptors and somatostatin analogues. 
Conclusion
Knowledge of the presence of CCK2 receptor in MTC 
patients may be an important indication for the choice 
of diagnostic and therapeutic procedures. The presence 
of both the receptor types, cholecystokinin-2/gastrin 
and somatostatin, is possibly an interesting combination 
as far as the therapeutic target is concerned. Further 
studies are required to determine its value in patient 
management.
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